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Abstract 
 
Background:  
Most developed countries have significantly decreased their incidence and mortality rates in 
cervical cancer in the past fifty years with effective screening programmes. In many 
developing countries cervical cancer is still a major problem. Rwanda is one of the worst 
affected countries with an incidence of 49/100 000 women. 
In 2011 the Rwandan government made an ambitious effort to start fighting the disease by 
mass vaccinating all girls, and start a screening programme like those present in the 
developed world. The vaccinations seem to have been a success, but little information is 
available on the progress of the screening programme, and of Rwandan womens’ attitudes to 
cervical cancer and screening. This study scrapes the surface of these questions.  
 
Purpose:  
To investigate the attitudes of Rwandan women to cervical cancer screening.  
 
Method:  
Using questionnaires from an ongoing cohort study, the attitudes of two cohorts of HIV 
positive and negative Rwandan women were investigated regarding previous screening and 
reasons for having or not having participated in screening, comparing the two cohorts. Each 
cohort included 200 women. 
  
Result: 
28.5% of the women in the HIV cohort and 6.5% of the women in the HIV negative cohort 
had been screened before, giving a 17.5% screening rate in the whole study population. The 
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most frequent reason for previous screening was recommendation from a doctor, which was 
more common in the HIV cohort. The most common reason to never have screened was 
unawareness of screening possibility. 
 
Conclusion: 
Few women had been screened before, and the main reason for this was unawareness of the 
availability of screening. The most common reason for having been screened before was 
recommendation from a doctor. This points to continuous contact with healthcare being a 
beneficial factor in likeliness to screen.  
 
 
Key words:, Cervical cancer screening, Rwanda, Attitudes, Screening frequency, Reason to 
screen 
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Background  
 
Cervical cancer and HPV  
Cervical cancer was, in 2008 estimated the third most common malignant disease among 
women globally, with 530 000 new cases annually, as well as the fourth deadliest, with an 
estimated 7.8 million years of life lost (1). If the disease is caught in its early stages it is 
highly curable (2), but if detected late in its course treatments rapidly become demanding and 
costly, and curative treatment might not be possible at all (3). Early detection is thus 
important to reduce the number of deaths due to cervical cancer in the world, as has already 
been done through screening programmes in many high income countries countries (4). 
It is well established that the Human Papilloma Virus (HPV) causes cervical cancer. Highly 
carcinogenic in other sites, such as the oropharynx, the anal region and the vulva as well, it is 
considered to be a necessary factor in the development of cancer in the cervix uteri. More 
than 150 different types of the virus have been found, and out of these 13 strains are 
considered high-risk types for oncogenic development of infected cells. HPV 16 and 18 stand 
out in the statistics and together account for about 70% of all cervical cancer cases in the 
world (5).  Especially HPV 16 seems to be associated with an increased risk, increasing in 
proportion to the degree of cytological abnormalities found in test materials (1).   
A majority of sexually active men and women will at some point during their lives be infected 
by HPV and it has been considered the most common sexually transmitted disease in the 
world. The prevalence was calculated to be 10.4% among 1 million women without 
cytological changes studied in a meta-analysis and even higher among women under the age 
of 25, reaching 16.9%. In 24% of the infected women in the same study, the HPV-virus was 
HPV 16 (6). More than 90% of HPV infections have regressed within a period of 6-18 months 
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(5). If the virus is not cleared by then, the infection will have a lower probability of being 
cleared at all and becomes chronic, which leads to the risk of developing cancer (7). Risk 
factors such as HIV and certain HPV-strains may promote a more persistent infection and 
thus elevate the risk of cancer further (6).  
 
Risk factors for HPV infection 
As the HPV virus is sexually transmitted many of the risk factors are linked to sexual 
behaviour and lifestyle. In many studies around the world early sexual debut, multiple sexual 
partners, use of hormonal contraceptives and a high number of pregnancies have been 
correlated to an increased risk to develop HPV infection (8). Of these risk factors, to have 
multiple sexual partners seems to be the clearest contributing factor, as has been seen in a 
large number of studies (8, 9, 10). A Spanish study on women being screened for cervical 
lesions showed that women with four or more lifetime sexual partners suffered a four times 
higher risk of having an HPV infection compared with women with only one sexual partner 
(11). It is also debated whether male circumcision have a protective effect on the transmission 
of HPV-infection and whether the use of condom protects against the virus (9, 12). Other, 
non-sexual factors where correlations are seen are young age, level of education, geographic 
region and tobacco use. Furthermore, immunodeficiency, due to HIV infection, 
immunosuppressant therapy after transplantation and malnutrition, may also promote the 
development of a chronic HPV infection and thereby increase the risk of cervical cancer. The 
number of pregnancies, oral contraceptives and smoking also seem to be independent risk 
factors of HPV infection (9). Young age is also a risk factor that stands out, however, like 
many other risk factors, it is also associated with sexual risk behaviour, which per se is a risk 
factor for HPV infection (6, 9, 11).  
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Cervical cancer in Rwanda and Sub-Saharan Africa 
Cervical cancer is today to a large extent a disease of the developing world with an estimated 
86% of new cases and 88% of deaths occurring in low income countries (4). In Africa, where 
a majority of the countries are considered low or middle income (13), malignant diseases in 
general are a growing problem due to an increase in life expectancy and prevalence of 
oncogenic risk factors. However, this issue still is not prioritized in most public health care 
systems in the region, due to limited resources and many other health issues that require 
attention (4). Among women cervical cancer is the second most frequently diagnosed cancer 
on the continent. In Sub-Saharan Africa the disease makes up almost 25% of all cancer cases 
in women (6, 14). In Rwanda it is the most common cancer among women, with an estimated 
incidence of 49 cases per 100 000 women (8). 
Cervical cancer and HIV: 
One contributing factor to the high incidence of cervical cancer in many Sub-Saharan 
countries is the high prevalence of HIV in the population. In 1993 cervical cancer was 
classified as an AIDS defining disease, and epidemiological studies have shown an 
association between HIV infection and cervical cancer, even though the association appears to 
be limited and its impact difficult to evaluate (15). As both HIV and HPV are sexually 
transmitted they also share many risk factors. However, there seems to be an independent 
increase in cervical cancer risk for HIV-infected individuals after stratifying for other 
confounding factors (9).  With the vast HIV-epidemic in Sub-Saharan Africa even a low 
association between HIV and cervical cancer is bound to have a major impact on cancer 
incidence (15). 
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Treatment of cervical cancer in Sub-Saharan Africa 
Few registered data on cancer stage at diagnosis in African countries exist, but much points to 
that a majority of cancer patients in the region are diagnosed at a late stage of their disease. In 
Harare, Zimbabwe, more than 90% of the cervical cancer cases in major hospitals only came 
to medical attention in more advanced stages of their cancer (4). 
Preferred methods for curative treatment of cervical cancer are surgery and radiotherapy. 
Lack of resources, such as facilities for radiotherapy and trained healthcare professionals as 
well as surgical tools make these treatments unavailable for a large portion of the population 
in many Sub-Saharan countries (4). Rwanda, with its 11 million inhabitants, opened its first 
oncologic centre at the Butaro District hospital, which serves as a national referral hospital for 
cancer care, in 2012. The centre offers diagnostics through histopathology, x-ray and ultra-
sound, and treatment in the form of surgery and chemotherapy. In spite of the fact that many 
of the patients are in need of radiotherapy, the centre does not have facilities to offer it. 
Patients are instead referred to Uganda for radiotherapy (3). However, after the linear 
accelerator in Mulago hospital, Kampala, broke in March 2016 the future availability of this 
treatment is uncertain (16).  
 
Prophylactic action 
There are two main ways to decrease the prevalence of cervical cancer (4). The first is 
through vaccination to avoid the infection that may lead to malignant development. The 
vaccines available today cover HPV 16 and 18, with or without the addition of low risk types 
HPV 6 and 11, and have in studies been shown to have an efficacy of at least 95% in 
preventing infection with the included HPV types in girls vaccinated before sexual debut, and 
to have an efficacy even higher for preventing cervical lesions due to the same virus types 
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(17). Education and change of behavioural patterns, are also important, although this is more 
difficult to implement as the risk factors for the infection, such as not using condom during 
intercourse, still are not fully understood (12, 17).  
 
The development of cervical cancer may also be prevented by screening for cytological 
changes, such as in the screening programmes with pap smears, that is taking a cytological 
sample from the cervix to be examined by pathologists for cytological changes, which are 
present in many developed countries. More recently other, less resource demanding, methods, 
for example visual inspection with dilute acetic acid (VIA) and HPV DNA-testing have been 
validated for screening, and might be more suitable techniques for low income settings (18).  
 
Primary prevention of cervical cancer in Rwanda  
Implementing preventative measures against cervical cancer puts high demands on a 
country’s health care system (17). The vaccines need to be included in national immunization 
programmes to reach a high enough coverage for a population effect by making them 
accessible for everybody and securing distribution to more rural areas where the vaccine 
otherwise might not be available (17). 
Rwanda was the first African country to introduce the HPV vaccine in their national 
vaccination schemes. In order to reach a high coverage of immunization the vaccination was 
school based, preceded by national information campaigns and with communal follow-up of 
girls not attending school. In its first year the Rwandan scheme reached a 93% coverage of 
sixth grade girls in the country. As the HPV vaccines have been included in the Global 
Alliance for Vaccines and Immunizations (GAVI), this might soon be the case in more low 
and middle-income countries due to a substantially lowered price (17).  However, obstacles 
for implementing and maintaining vaccination programmes exist. First there is the question of 
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financing the programme. Even with GAVI coverage the costs for efforts such as the one in 
Rwanda are high for a low-income country. Apart from the cost of the vaccine itself the 
infrastructural requirements for distributing three doses of vaccine per girl are many, i.e. 
storage of vaccine without breaking the cold chain, distribution, transportation, personnel and 
systems for monitoring the programme, administration and other staff.  The clinical effect of 
the vaccination programme will not be possible to evaluate for another ten to twenty years, 
since cytological changes take years to develop. It is also unclear how vaccinations will affect 
the prevalence of other high risk HPV types. Thus vaccination cannot be the only measure 
taken to decrease the incidence of cervical cancer. 
 
Cervical cancer screening methods 
Early detection of cervical lesions is essential to effectively reduce death and mortality in 
cervical cancer in Rwanda.  In Sweden incidence and mortality rates have decreased by over 
50% since the introduction of screening with pap smears in the mid-sixties (19). Pap smears, 
however, are costly and highly demanding for the health care infrastructure (4), requiring both 
materiel and trained health care workers to collect and store the samples, as well as 
pathologists to interpret the results, all of which exist in shortage in large parts of Sub-
Saharan Africa (17, 18).  
Introducing screening programmes using less means-requiring methods such as VIA or 
Lugol’s Iodine (VILI), where dilute acetic acid or Lugol’s Iodine respectively are applied to 
the cervix has been suggested as a possible solution. Especially VIA is considered an 
appropriate method for less developed health care systems, being inexpensive and readily 
available. With VIA it is also possible to treat lesions with cryotherapy in the same session 
immediately after diagnosis (17).  
 
	   11	  
Another method that has gained scientific support is HPV-DNA-testing with PCR. A major 
advantage of this kind of test is that the samples can be self-collected, and thus less personnel 
is needed for collecting the samples. Many of the techniques used for HPV analysis are still 
too expensive and advanced for hospital laboratories in Sub-Saharan Africa though, and thus 
not feasible for large-scale screening programmes. However, Care-HPV, which only tests for 
14 of the most common high-risk HPV-types, might be a realistic method in developing 
countries (17). According to the WHO guidelines from 2013 the recommended screening 
method when possible is the HPV DNA-test, followed by VIA to test for existing lesions. If 
HPV DNA-test is not available, VIA can be used directly to identify lesions (20).  
 
In the launch of a strategic campaign against cervical cancer in Rwanda in 2011, HPV-DNA-
test followed by VIA was the preferred screening method in the screening program (2). 
However little data exists on how the Rwandan screening program proceeds, and therefore it 
is difficult to evaluate how successful the programme has been. Gakidou et al found in 2008 
that only 19 % of women in all developing countries are screened for cervical cancer, with 
significantly lower levels in several countries in Sub-Saharan Africa (21), and in a study on 
the knowledge attitudes and practices regarding cervical cancer in Rwanda’s neighbouring 
country Democratic Republic of Congo, only 8.6% of the studied women had previously been 
screened (22). 
 
Knowledge about cervical cancer and screening programs 
Why women do or do not seek screening is a complex question where demographic factors 
such as age, marital status and education level as well as knowledge and attitude to cervical 
cancer and the procedure of screening play an important role. The accessibility to nearby 
screening facilities is also an important aspect. One study conducted in rural Tanzania 
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concluded that knowledge of cervical cancer and screening, and accessibility were the main 
factors influencing the decision to screen (23). Previous studies regarding the knowledge and 
attitudes of the Rwandan population regarding HPV-infection, cervical cancer and the 
benefits of screening are scarce, but a few studies from other Sub-Saharan countries exist. 
These point to a generally low knowledge in the region about cervical cancer, its causes, risk 
factors and prophylactic measures such as screening and vaccination (22, 24, 25, 26). Apart 
from knowledge of the possibility, important factors for choosing to screen for cervical cancer 
seem to be perceived risk of cancer, time and money for screening and travel, geographical 
accessibility, and attitudes of husbands or partners to the procedure (27). 
 
Aim of study 
The aim of this study was to investigate the attitudes towards cervical screening among one 
cohort of HIV patients and one cohort of healthy controls in Rwanda.  
 
This was done by attempting to answer the following questions:  
-­‐   How many of the women had previously been screened for cervical lesions? 
-­‐   What were the main reasons for previously having been screened respectively not 
having been screened? 
-­‐   Did the attitudes to cervical cancer screening differ between HIV positive and HIV 
negative women? 
 
Method 
This master thesis was performed as a part of a larger, ongoing prospective cohort study 
within the Sweden-Rwanda collaboration (SIDA): Project “Immunological responses in the 
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cervix in response to HPV infection in a cohort of HIV-infected and non-infected Rwandan 
women”.   
The first cohort contained 200 HIV-negative women who were recruited at the gynaecological 
and obstetric departments of the University Teaching Hospitals in Kigali (CHUK) and Butare 
(CHUB). The second cohort consisted of 200 HIV positive patients that were recruited at the 
HIV-clinic at CHUK. In the HIV-negative cohort many women sought out the study 
themselves to participate after hearing about it from friends and family. If the women met the 
inclusion criteria they were included after signing a written consent form. 
 
Inclusion criteria for women recruited at the gynaecological clinics of CHUK and CHUB:    
-­‐   Voluntary participation and signed consent form 
-­‐   Age over 17 years 
-­‐   Literacy in Kinyarwanda, French or English 
-­‐   No plans to relocate in the next two years 
 
Inclusion criteria for women recruited at the HIV clinic at CHUK: 
-­‐   All criteria listed for the gynaecological clinic cohort 
-­‐   HIV-infection and enrolment at an HIV clinic 
 
Exclusion criteria for participation in the study:  
-­‐   Presenting any known disease likely to limit life expectancy to less than 24 months 
-­‐   Presenting other factors suggesting inability to comply with study protocol 
-­‐   Cervical cancer diagnosis prior to time of inclusion 
-­‐   Known vaginal or cervical infection besides HPV at time of inclusion 
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-­‐   Presenting any condition or major comorbidity that the study investigators believed 
would compromise the patient’s ability to comply with the requirements of the study 
 
Data collection 
The participants were interviewed by a nurse according to a standardized questionnaire 
(appendix 1 and 2), available in English, French and Kinyarwanda, regarding demographic 
data, i.e age, educational level, occupation, marital status and current partner, number of live 
births; sexual history, including number of sexual partners, previous sexually transmitted 
diseases, and use of contraceptives; and questions regarding previous cervical screening. 
After this the patients underwent a pelvic examination by the study physician, and sampling 
from the cervix for HPV screening and cytology was performed.  
 
Analysis:  
I processed the data regarding previous screening and reasons for choosing or not choosing to 
screen in SPSS with descriptive statistics and presented in tables and charts according to 
cohort.  
The data regarding previous screening was also processed with binary logistic regression in 
SPSS and presented as odds ratios adjusted for age, education and number of live births.  
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Ethics 
The study was approved by the Ethical Review Board of the University of Gothenburg and 
the University of Rwanda. Participation in the study was voluntary. Patients were provided 
with both written information in English, French and Kinyarwanda, as well as information 
given orally via medical staff at the hospital in their preferred language. The information 
given included information about the study, its aims and how the data would be used. It was 
possible to withdraw from the study at any time without stating a reason for it. The patients 
were also informed about the confidentiality policy and the handling of collected data.  
 
Results  
 
General and Demographics: 
In total answers from 400 women included at the start of the larger study were collected, i.e. 
200 at the HIV clinics and 200 recruited at the gynaecological clinics. The demographic data 
is presented in table 1. Worth noting is that 111 of 200 women recruited at the gynaecological 
clinic were under the age of 40, while 159 out of 200 women recruited at the HIV clinic were 
over the age of 40. Regarding marital status 113 out of 200 women in the HIV cohort were 
widowed, while 25 women in the gynaecological cohort gave the same answer. Furthermore, 
94 of 200 women in the gynaecological cohort worked in farming, while the corresponding 
figure in the HIV cohort was 7 women, whereas 129 women in the HIV cohort answered 
“other” when asked of their occupation, as compared to 15 in the gynaecological cohort.  
 
Previous screening:  
All 400 women answered the questionnaires, and 70 gave a positive answer to the question 
“Have you ever been screened for cervical cancer” (Table 1) giving a previous screening 
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percentage of 17.5% in the entire study population. Of these 57 women, or 81.4% of the 
previously screened population had been recruited at the HIV clinic and 13, 18.6%, at the 
gynaecological clinic (Table 2), giving the HIV group a significantly higher previous 
screening rate than the women recruited at the gynaecological clinic, with an odds ratio of 5.5 
(p<0.001) when adjusted for age, education and number of live births. None of these other 
factors had significant odds ratios in the adjusted model though. (Table 3). 
	  
 
Reasons for previous screening: 
Women had been screened due to recommendation from doctors. This was particularly the 
case for the HIV cohort. 54 women (77.1 % of the positive respondents), of which more than 
90% belonged to the cohort from the HIV clinics, stated this as their reason for previous 
screening. 13 women said that they had “decided on their own”, with 7 respectively 6 
respondents in the gynaecological cohort and the HIV cohort. Only 3 had been advised by a 
friend (table 4) 
 
Reasons for not having previously screened: 
 Of the 330 who had not previously been screened 2 women did not answer the question of 
why they had not been screened.  57.6% stated that their reason for not having been screened 
was that they “did not know about it”.  62.6% of the gynaecology cohort gave this answer, 
whereas 37.4% of the women in the HIV positive cohort did the same. Fifteen percent of the 
negative respondents stated that they had no money to pay for the screening, with a higher 
frequency in the HIV cohort. Women also stated that they did not know where to be examined 
(12.5%), did not think screening was necessary (9.8%), and 4.3% stated fear of the outcome 
of the test as their main reason for not having screened before (table 5) 
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Tables:  
Table 1: Demographic data on the participating women in numbers and percent according to 
cohort. 
 Cohort 
Variable Gynaecological clinic HIV clinic 
 Number Percentage(%) Number Percentage(%) 
Age in years (n=200)  (n=200)  
<30 27 13.5 3 1.5 
30-39 84 42 38 19 
40-49 62 31 90 45 
>50 
 
27 13.5 69 34.5 
Education (n=200)  (n=200)  
None 12 6 17 8.5 
Primary school 87 43.5 87 43.5 
Secondary school 54 27 62 31 
University 45 22 17 8.5 
Other 
 
2 1 17 8.5 
Current marital status (n=200)  (n=200)  
Married 132 66 66 33 
Male partner, unmarried 19 9.5 1 0.5 
Separated/divorced 12 6 14 7 
Widow 25 12,5 113 56.5 
Single 
 
11 5.5 5 2.5 
Occupation (n=200)  (n=200)  
Farming 94 47 7 3.5 
Civil servant 19 9.5 19 9.5 
Businesswoman 34 17 36 18 
Health worker 31 15.5 - - 
Student 5 2.5 - - 
Other  15 7.5 129 64.5 
Unemployed 
 
2 1 9 4.5 
Number of live births (n=197)  (n=200)  
None 25 12.7 8 4 
1-3 101 50.3 103 51.5 
>4 71 36 89 44.5 
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Table 2: Number and percentage of women previously screened for cervical cancer 
 Have you ever been screened for cervical cancer? 
 Yes No  
Cohort Number Percentage 
(%) 
Number Percentage 
(%) 
Total number of 
women 
Gynaecological 
clinic 13 6.5 187 93.5 200 
HIV clinic 
 57 28.5 143 71.5 200 
Total study 
population 70 17.5 330 82.5 400 
	  
 
 
Table 3: Unadjusted and adjusted odds ratios for likeliness to screen for cervical cancer  
confounding factors: age, education and number of live births 
 Unadjusted Adjusted 
 OR (95% CI) P-value OR(95% CI) P-value 
Cohort     
Gynaecological Reference - Ref. - 
HIVclinic 5.7 (3.0-11) <0.001** 5.5 (2.7-11) <0.001** 
     
Age     
<30 Ref. - Ref. - 
30-39 8.6 (1.1-67) 0.039* 2.1 (0.24-18) 0.51 
40-49 2.1 (1.0-4.4) 0.041* 1.1 (0.45-2.5) 0.91 
>50 1.1 (0.60-2.1) 0.73 0.96 (0.49-1.9) 0.90 
     
Education     
None Ref. - Ref. - 
Primary school 2.9 (0.69-12) 0.15 2.0 (0.44-8.9) 0.37 
Secondary 
school 2.1 (0.75-6.0) 0.16 1.4 (0.45-4.1) 0.58 
University  2.2 (0.75-6.5) 0.15 1.4 (0.46-4.3) 0.55 
Other 2.2 (0.82-9.0) 0.10 1.0 (0.28-4.0) 0.95 
     
Live births     
None Ref.  Ref. - 
1-3 8.9 (1.2-68) 0.034 5.4 (0.64-45) 0.12 
>4 1.5 (0.86-2.5) 0.17 1.4 (0.77-2.5) 0.27 
     
     
*:P<0.05 
**: P<0.001 
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Table 4: Numbers and percentages of reasons for previous cervical cancer screening 
 Cohort  
 Gynaecological clinic HIV clinic All women previously screened 
Reason for 
previous 
screening 
Number Percentage 
(%) 
Number  Percentage 
(%) 
Number Percentage 
(%) 
 
Doctor’s request 
 
5 
 
38.5 
 
49 
 
86 
 
54 
 
77.1 
Own decision 7 53.8 6 10.5 13 18.6 
Recommendation 
from a friend 
1 7.7 2 3.5 3 4.3 
Total  13 100 57 100 70 100 
	  
	  
Table 5: Numbers and percentages of reasons for never having screened for cervical cancer 
 Cohort   
 Gynaecological 
clinic HIV clinic 
All women never 
screened 
Reason for never 
having screened 
Number Percentage 
(%) 
Number Percentage 
(%) 
Number Percentage 
(%) 
Did not know about 
it 119 63.3 71 49.7 190 57.6 
No money to pay 12 6.4 37 25.9 49 14.8 
Don’t know where to 
go 26 13.9 15 10.5 41 12.4 
Unnecessary 21 11.2 11 7.7 32 9.7 
Fear of outcome 5 2.7 9 6.3 14 4.2 
Feart of painful 
examination 1 0.5 - - 1 0.3 
Other 1 0.5 - - 1 0.3 
Missing 
 
2 1.1 - - 2 0.6 
Total 187 100 143 100 330 100 
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Discussion 
 
General discussion 
Our results showed a previous screening percentage of 17.5% in the entire study population 
and 6.5% respective 28.5% in the gynaecological and HIV clinic cohorts. The most frequently 
named reason for previous screening was advice from a doctor whereas the most stated reason 
for not having been screened was unawareness of the possibility.  
The number of women who had previously been screened for cervical lesions was low. 
However, when splitting the results according to cohort, most of the previously screened 
women belonged to the HIV clinic cohort, whereas only 6.5% of the women in 
gynaecological clinic cohort had been screened. Certain demographic factors, such as age and 
education differed a largely between the groups, acting as possible confounding factors, but 
when adjusting for some of these factors, a comparison between the two groups still gave a 
significant higher odds ratio in the cohort recruited at the HIV clinic (table 3) whereas none of 
the other factors in the model gave a p-value <0.05 in the adjusted model. Thereby the 
enrolment at an HIV clinic can be seen as a beneficial factor for likeliness to screen for 
cervical cancer. The factors that could not be adjusted for in the model were occupation and 
marital status. The categories used to define occupation did not convey information on the 
socio-economic situation of the participants, which would have been more interesting to have 
access to in the analysis, and was thus excluded. The marital status however has been seen as 
a factor which may influence the decision-making of whether or not to screen in other studies 
and would have been interesting to adjust for, especially as the cohorts differed  substantially 
in this aspect.  
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By far the most frequently stated reason for having participated in cervical screening prior to 
inclusion in the main study was to have been recommended to do so by a doctor; 77.1% of 
women with previous screening experience gave this answer. This was most common in the 
HIV cohort, suggesting that the HIV patients’ increased contact with health care professionals 
makes them likelier to make use of cervical screening possibilities. Similar results have been 
seen in other African studies. One Gabonese study stated that also there, the main reason 
women screened for cervical cancer was their doctor’s recommendation (25). A Kenyan study 
saw a significant association between duration of HIV diagnosis and both knowledge and 
acceptance of cervical screening, stating that this likely was due to the HIV patients’ 
increased access to health education (28). This indicates that a continuous health care contact 
is beneficial for the patient’s likeliness to screen for cervical lesions. 
 
A majority of the women who had not been screened before stated that their main reason for 
not having done so was that they did not know about it. This points to a lack of knowledge of 
the importance to screen in Rwandan society. Little or no data is published on this topic in 
Rwanda, though studies from neighbouring countries support that lack of knowledge of 
cervical cancer screening is common in the region (22, 23, 27) 
 
Financial issues for not being screened was particularly common in the HIV cohort.  
Cervical cancer screening is free in Rwanda, but still about 25% of the women in the HIV 
cohort stated that they could not afford it as their reason for not having screened.  
Among the women in this population, few were worried about the examination itself or the 
results it might bring.  
No major, more complex or in-depth conclusions regarding the reasons for Rwandan women 
to partake in cervical cancer screening can be made from the results above.  Tendencies can, 
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however, be seen in the answers, such as that a majority of the participating women had not 
been screened for cervical lesions and were unaware of their possibility to do so, in spite of 
Rwanda’s explicit goal of having eradicated cervical cancer by 2020 (29). It is also notable 
that 14.9 % of the women who had not screened had refrained from doing so based on not 
having the money to pay for the test, even though cervical cancer screening is free in Rwanda. 
This could however also be attributed to lack of screening facilities and the need to pay for 
travel to be able to screen and not necessarily lack of knowledge of free screening. 
Generally though, our results point to a problem in raising the screening rates being the low 
knowledge of the procedure and its availability among eligible women.  
 
This is further supported by the higher percentage of women having previously been screened 
for cervical cancer in the cohort enrolled at the HIV clinic compared to the women recruited 
at the gynaecological clinics, as well as that a majority of the women who had been screened 
before had done so at request from their doctors. The higher number in the group enrolled at 
the HIV-clinic is most likely due to the steady health care contact these women have 
compared to the general female Rwandan population. Moreover, the awareness of the risk of 
developing cervical cancer among women with HIV, may also be higher than in the 
population in general.  
 
However, only 28.5% of the women recruited at the HIV clinic had been screened for cervical 
lesions, and 37.6% of the women in the cohort still stated that they were unaware of cervical 
cancer screening. This indicates that even these established contacts do not guarantee proper 
information about the necessity of cervical cancer screening.  
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One possibility could be to educate healthcare professionals in general about inquiring and 
informing their patients of cervical screening and urge them to be screened. This 
“opportunistic screening” seems to be effective, judging from this being the clearly most 
frequent reason for the women in both this and other studies in Sub-Saharan Africa to have 
been screened before (24). This would also be a possible opportunity to register participation 
in the cervical cancer screening in order to properly evaluate the screening programme and 
improve it. Considering Rwanda’s very ambitious comprehensive cervical cancer programme, 
the lack of data on the programme and on awareness of the disease in the population should 
be a cause of concern, as lack of knowledge of the availability of screening possibilities is a 
clear barrier to its generalised practice (27). 
 
Thus cervical cancer is still an important health issue in Rwanda, even though efforts have 
been made to decrease its impact on the country, including the successful vaccination 
programme.  
 
Limitations:  
This master thesis is based on data collected from questionnaires that did not have the main 
objective to assess the attitudes of Rwandan women to cervical cancer screening, meaning 
that questions that could have given a deeper understanding of the attitudes investigated were 
not asked. However, the present data indicates the importance to further assess attitudes of 
Rwandan women to cervical cancer screening in the future.  
 
 Another limitation is that the gynaecological cohort was mainly “recruited” through word of 
mouth from other participants and thus cannot be assumed to be a representative sample of 
	   24	  
the female Rwandan population. However, how quickly this cohort was filled indicates a 
willingness among Rwandan women to screen if aware of the possibility.  
 
Also the cohorts differed in composition regarding demographic factors such as age, 
education, marital status, number of live births and employment, which could act as 
confounding factors. However, the statistical model would not allow for adjustment for all of 
them, and therefore the adjusted results have to be regarded with this in mind, even if the 
statistical analysis that could be performed showed a very strong, statistically significant 
correlation between screening frequency and being enrolled at an HIV clinic. 
 
Conclusion 
 
My master thesis has begun to examine the attitudes to cervical screening among Rwandan 
women, finding that only 17.5% of women studied had previously been screened for cervical 
lesions, with five times higher screening rate for women enrolled at an HIV clinic as 
compared to patients recruited from a gynaecological clinic. The main reason for the low 
screening numbers seem to be lack of knowledge about cervical cancer screening, but little 
data exist on the matter. A study regarding the knowledge of cervical cancer, its causes and 
screening should therefore be performed among Rwandan women, as has already been done 
in many other Sub-Saharan countries with similar figures in prevalence and mortality, to 
further support the building of a future well-functioning cervical cancer screening programme 
in Rwanda. 
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Populärvetenskaplig sammanfattning: 
Rwandiska kvinnors inställning till livmoderhalscancerscreening 
 
Detta examensarbete genomfördes som del i ett större projekt om HPV-infektioner hos 
hivpositiva och -negativa  rwandiska kvinnor och hade som mål att undersöka rwandiska 
kvinnors inställning till livmoderhalscancerscreening. Detta ansågs viktigt då det är välkänt 
att screening kraftigt minskar antalet nya fall och dödligheten i livmoderhalscancer, då man 
kan hitta cellförändringar på ett tidigt stadium och behandla dessa innan de har utvecklats till 
cancer. 
 
 I Rwanda är livmoderhalscancer för närvarande en betydande orsak till sjuklighet och för 
tidig död och regeringen har påbörjat ett arbete med att bekämpa sjukdomen genom att införa 
allmän vaccinering av flickor mot högrisk-HPV-virus. Det är dock mer oklart hur det står till 
med screening i landet, då mycket lite data finns att tillgå på detta område. 
 
I frågeformulären till den större studien efterfrågades bland annat tidigare 
screeningerfarenhet, och vad som var orsaken till att man hade, eller inte hade, screenat sig 
tidigare. Dessa svar analyserades och jämfördes sedan mellan de båda kohorterna för att få en 
bild av screeningprevalensen bland hivpositiva och-negativa kvinnor. I studien ingick 200 
hivpositiva kvinnor, som rekryterades på hivkliniken i på universitetssjukhuset i huvudstaden 
Kigali, och 200 hivnegativa kvinnor som rekryterades från gynekologiska klniker på 
universitetssjukhusen i Kigali och Butare i landets södra del. 
 
Våra resultat visade att endast 17.5% av kvinnorna i studien tidigare hade screenat sig. Om 
man tittade kohortvis var det mycket vanligare att ha screenat sig i den hivpositiva gruppen än 
i den hivnegativa. Den vanligaste anledningen kvinnorna angav till att ha screenat sig var att 
deras läkare hade rått dem att göra det. Också detta var vanligare bland de hivpositiva 
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kvinnorna. Den vanligaste orsaken till att inte ha screenat sig var att man inte kände till 
möjligheten att screena sig för livmoderhalscancer, följt av att det var för dyrt och att man inte 
visste vart man skulle vända sig för screening.  
 
Den högre screeningfrekvensen i hivkohorten och att den främsta screeningorsaken var råd 
från läkare tolkas som att kontinuerlig kontakt med vård är en gynnsam faktor för 
screeningbenägenhet. Bristen på kunskap om livmoderhalscancerscreening får ses som ett 
problem för att få upp screeningfrekvensen i Rwanda. Dock skulle mer detaljerade studier för 
att kartlägga kunskap och attityd behöva göras för att få en helhetsbild av problematiken och 
vad som kan göras för att förbättra screeningdeltagandet i landet. . 
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Appendix 1 – Questionnaire cohort 1 
 
 
Cohort 1: Women seeking voluntarily a cervical cancer-screening test /Itsinda rya 1:Abagore 
basa gusaba gukorerwa isusumwa rya cancer y’inkondo y’umura ku bushake bwabo 
Questionnaire identification number/Umubare uranga ifishi y’ibibazo mu bushakashatsi | _ | _ | _ | 
Participant Identification number in the study/Umubare uranga uwagize uruhare mu gusubizo _ | _ | 
_ | 
Interviewer Name /Amazina Y’ubaza............................................ 
Interview Date /Italiki y’ibazwa | _ | _ | | _ | _ | | _ | _ | _ | _ | 
Day/Umunsi Month /Umunsi Year/Umwaka 
I will ask some questions that will be recorded in this notebook. I must say that all the lady 
answering the interview will be strictly confidential, and the information gathered from various 
women participating in the study will be used only in scientific reports, without personal 
identification./Ngiye kukubaza ibibazo maze ibisubizo byandikwe muri aka gatabo.Ndakwizeza neza 
ko abari abari muri ubu bushakashatsi bose bazagira ibanga ku bisubizo uri butange kandi ko 
bizakoreshwa gusa mu bijyanye n’intego z’ubu bushakashatsi. 
Instructions: 
1. For multiple choice question ,encircle correct answer(s) 
2. For sort answer questions, fill in gap provided  1. ###What is your age? /Ufite imyaka y’amavuko ingaye? ………………. | _ | _ | 2. What is your Highest educational level attained? /Ni uruhe rwego rwanyuma rw’amashuri 
warangije? (Hitamo igisubizo kimwe) 
a. None/Ntiyize 
b. Incomplete primary school/Ntiyarangije abanza 
c. Complete primary school/Yarangije amashuri abanza 
d. Secondary school incomplete/Ntiyarangije ayisumbuye 
e. Complete Secondary school/Yarangije ayisumbuye 
f. Incomplete University/Ntiyarangije kaminuza 
g. Complete University/Yarangije kaminuza 
h. Others (Specify) /Ibindi(Sobanura).......... 3. Occupation/Umurimo 
a. Farming/Umuhinzi 
b. Civil servant/Umukozi wa Leta 
c. Business/Arikorera Ku giti cye 
d. Health worker/Akora mu buvuzi 
e. Others (specify)/Ibindi (Sobanura)   4. Currently, Mrs. /Ubu tuvugana Madamu 
a. Is married/Yarashatse/Arubatse 
b. Has a male partner but not married/Afite uwo mubana ku bwumvikane 
c. Is separated/divorced/Yatandukanye n’uwo mwashakanye 
d. Is widow/Ni umupfakazi 
e. Is single (never been married or lived with a partner)/Ni Ingaragu 
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Appendix 2 – Questionnaire cohort 2 
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